| Trial ID: | L0130 |
| Source ID: | NCT03195023
|
| Associated Drug: |
Lisinopril
|
| Title: |
Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)
|
| Acronym: |
PROERCAN01
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Renal Insufficiency, Chronic|Proteinuria
|
| Interventions: |
DRUG: Lisinopril|DRUG: Amlodipine
|
| Outcome Measures: |
Primary: Chronic kidney disease progression, Increase of baseline creatinine during follow up period, 3 years | Secondary: Security of RAS blockers in elderly patients, Evaluate the frequency of hiperpotassemia (K\>5.5 mmol/l), 3 years|Security of RAS blockers in elderly patients, Evaluate the frequency of acute kidney failure (\>Cr 0.3 mg/dl), 3 years|Effect of RAS blockers on mortality in elderly patients, Evaluate the number and cause of deaths in the study population, 3 years|Effects of RAS blockers on cardiovascular risk in elderly patients, Evaluate and classify cardiovascular events (heart failure, acute coronary syndrome, peripheral vasculopathy) during the follow up period, 3 years
|
| Sponsor/Collaborators: |
Sponsor: Hospital General Universitario Gregorio Marañon
|
| Gender: |
ALL
|
| Age: |
OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
106
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2015-06
|
| Completion Date: |
2022-12
|
| Results First Posted: |
|
| Last Update Posted: |
2019-02-22
|
| Locations: |
Gregorio Maranon Hospital, Madrid, 28007, Spain
|
| URL: |
https://clinicaltrials.gov/show/NCT03195023
|
